Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2025 12:30 ET | Source: MannKind

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

MANNKIND TEAMS UP WITH JUNCOS HOLLINGER RACING (JHR) DRIVER CONOR DALY TO DRIVE AWARENESS OF DIABETES AND INNOVATIVE TREATMENT OPTIONS
March 10, 2025 06:05 ET | Source: MannKind

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
February 26, 2025 16:05 ET | Source: MannKind

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MANNKIND CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
February 19, 2025 16:05 ET | Source: MannKind

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), will release its 2024 fourth quarter and full year financial results after market...
February 06, 2025 16:05 ET | Source: MannKind

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
January 06, 2025 16:30 ET | Source: MannKind

MannKind Expands Executive Leadership Team

Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind...
December 18, 2024 07:00 ET | Source: MannKind

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH
December 16, 2024 06:05 ET | Source: MannKind

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
December 11, 2024 06:00 ET | Source: MannKind

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
November 07, 2024 16:02 ET | Source: MannKind

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE